ARGX vs. KYMR: argenx vs. Kymera Therapeutics Stock Comparison

Company Profile

argenx (ARGX) and Kymera Therapeutics (KYMR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Kymera Therapeutics (KYMR) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Kymera Therapeutics (KYMR) has an aggressive beta of 2.00, indicating higher sensitivity to broad-market moves, while argenx (ARGX) is defensive at 0.45 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

argenx (ARGX) has no ROE value reported for this period; Kymera Therapeutics (KYMR) reports a negative figure of -27.29%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

argenx (ARGX) at 31.73% converts revenue to bottom-line profit above its industry’s benchmark range, while Kymera Therapeutics (KYMR) at 0.00% keeps roughly the typical share for its industry.

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile argenx (ARGX) reports 36.27%, ranking against industry peers normally.

Profitability Metrics

Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Kymera Therapeutics (KYMR) at -16.70% is in the bottom quartile, showing a clear gap in revenue momentum.

Only one side can be read here: argenx (ARGX) reports EPS growth of 53.13%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Kymera Therapeutics (KYMR) shows current ratio of 11.13 against its industry benchmark, while argenx (ARGX) has no reading this period.

argenx (ARGX) at 0.01 keeps leverage in the lower industry quartile, while Kymera Therapeutics (KYMR) at 0.05 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither argenx (ARGX) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither argenx (ARGX) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: argenx (ARGX) trades at 32.12 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

argenx (ARGX) at 9.86 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

Both look rich against book: Kymera Therapeutics (KYMR) at 6.96 sits in the upper P/B ratio quartile, and argenx (ARGX) at 172.23 prices even higher, above its industry range.

Valuation Metrics